NASDAQ:HALOHalozyme Therapeutics Stock Price, Forecast & News

Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HALO shares have increased by 55.7% and is now trading at $28.37. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Halozyme Therapeutics.

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Halozyme Therapeutics.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.04) EPS for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.02. The biopharmaceutical company had revenue of $25.30 million for the quarter, compared to analysts' expectations of $42.96 million. Halozyme Therapeutics had a negative net margin of 48.75% and a negative return on equity of 48.92%. The firm's quarterly revenue was down 55.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.01 earnings per share. View Halozyme Therapeutics' earnings history.

Halozyme Therapeutics issued an update on its FY20 earnings guidance on Monday, May, 11th. The company provided EPS guidance of $0.60-0.75 for the period, compared to the Thomson Reuters consensus estimate of $0.62. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $239.41 million.

10 brokers have issued 1-year price targets for Halozyme Therapeutics' shares. Their forecasts range from $20.00 to $39.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $29.80 in the next year. This suggests a possible upside of 5.0% from the stock's current price. View analysts' price targets for Halozyme Therapeutics.

News coverage about HALO stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Halozyme Therapeutics earned a news impact score of -1.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Halozyme Therapeutics.

Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Gilead Sciences (GILD), NIC (EGOV), Micron Technology (MU), Allergan (AGN) and Aegean Marine Petroleum Network (ANW).

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Halozyme Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.18%), MERIAN GLOBAL INVESTORS UK Ltd (0.05%) and Diversified Trust Co (0.01%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros, Kenneth J Kelley, Michael J Labarre and Randal J Kirk. View institutional ownership trends for Halozyme Therapeutics.

HALO stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Dimitrios Chondros, and Michael J Labarre. View insider buying and selling activity for Halozyme Therapeutics.

HALO stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., and Diversified Trust Co. View insider buying and selling activity for Halozyme Therapeutics.

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of HALO stock can currently be purchased for approximately $28.37.

Halozyme Therapeutics has a market capitalization of $3.85 billion and generates $195.99 million in revenue each year. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.

The official website for Halozyme Therapeutics is www.halozyme.com.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]